AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ARCA BIOPHARMA, INC.; ATLAS MERGER SUB CORP.; ATLAS MERGER SUB II, LLC; and ORUKA THERAPEUTICS, INC. Dated as of April 3, 2024Agreement and Plan of Merger and Reorganization • April 3rd, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledApril 3rd, 2024 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of April 3, 2024, by and among ARCA BIOPHARMA, INC., a Delaware corporation (“Parent”), ATLAS MERGER SUB CORP., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), ATLAS MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and ORUKA THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined Section 1.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: AgeX Therapeutics, Inc., a Delaware corporation; CANARIA TRANSACTION CORPORATION, an Alabama corporation; and Serina THERAPEUTICS, INC., an Alabama corporation Dated as of August 29, 2023Agreement and Plan of Merger and Reorganization • August 30th, 2023 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 30th, 2023 Company Industry Jurisdiction
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023Agreement and Plan of Merger and Reorganization • July 7th, 2023 • MorphImmune Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 7th, 2023 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 29, 2023, by and among IMMUNOME, INC., a Delaware corporation (“Parent”), IBIZA MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and MORPHIMMUNE INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023Agreement and Plan of Merger and Reorganization • June 29th, 2023 • Immunome Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 29th, 2023 Company Industry Jurisdiction
AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONAgreement and Plan of Merger and Reorganization • May 30th, 2023 • Kubient, Inc. • Services-computer integrated systems design • Delaware
Contract Type FiledMay 30th, 2023 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of May 24, 2023, by and among Kubient, Inc., a Delaware corporation (“Parent”), ADM Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Adomni, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONAgreement and Plan of Merger and Reorganization • May 30th, 2023 • Kubient, Inc. • Services-computer integrated systems design • Delaware
Contract Type FiledMay 30th, 2023 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of May 24, 2023, by and among Kubient, Inc., a Delaware corporation (“Parent”), ADM Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Adomni, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ANGION BIOMEDICA CORP., a Delaware corporation; ARKHAM MERGER SUB, INC., a Delaware corporation; and elicio therapeutics, inc., a Delaware corporation Dated as of January 17, 2023Agreement and Plan of Merger and Reorganization • January 17th, 2023 • Angion Biomedica Corp. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 17th, 2023 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of January 17, 2023, by and among ANGION BIOMEDICA CORP., a Delaware corporation (“Parent”), ARKHAM MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ELICIO THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GRAYBUG VISION, INC., a Delaware corporation; CAMARO MERGER SUB, INC., a Delaware corporation; and CALCIMEDICA, INC., a Delaware corporation Dated as of November 21, 2022Agreement and Plan of Merger and Reorganization • November 22nd, 2022 • Graybug Vision, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 22nd, 2022 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of November 21, 2022, by and among GRAYBUG VISION, INC., a Delaware corporation (“Parent”), CAMARO MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and CALCIMEDICA, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022Agreement and Plan of Merger and Reorganization • November 21st, 2022 • Bell Robert G. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 21st, 2022 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022Agreement and Plan of Merger and Reorganization • November 18th, 2022 • Tanimoto Sarina • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 18th, 2022 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022Agreement and Plan of Merger and Reorganization • November 8th, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 8th, 2022 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONAgreement and Plan of Merger and Reorganization • August 11th, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 11th, 2022 Company Industry Jurisdiction
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022Agreement and Plan of Merger and Reorganization • July 21st, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 21st, 2022 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SUNESIS PHARMACEUTICALS, INC. a Delaware corporation; SOL MERGER SUB, INC., a Delaware corporation; and VIRACTA THERAPEUTICS, INC., a Delaware corporation Dated as of November 29, 2020Agreement and Plan of Merger and Reorganization • November 30th, 2020 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 30th, 2020 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of November 29, 2020, by and among Sunesis Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Sol Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Viracta Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: NTN BUZZTIME, INC. a Delaware corporation; BIT MERGER SUB, INC. a Delaware corporation; and BROOKLYN IMMUNOTHERAPEUTICS LLC a Delaware limited liability company Dated as of August 12, 2020Agreement and Plan of Merger and Reorganization • August 14th, 2020 • NTN Buzztime Inc • Television broadcasting stations • Delaware
Contract Type FiledAugust 14th, 2020 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of August 12, 2020, by and among NTN BUZZTIME, INC., a Delaware corporation (“Parent”), BIT MERGER SUB, INC., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and BROOKLYN IMMUNOTHERAPEUTICS LLC, a Delaware limited liability company (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: REXAHN PHARMACEUTICALS, INC., a Delaware corporation; RAZOR MERGER SUB, INC., a Delaware corporation; and OCUPHIRE PHARMA, INC. a Delaware corporation Dated as of June 17, 2020Agreement and Plan of Merger and Reorganization • August 14th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 14th, 2020 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 17, 2020, by and among REXAHN PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), RAZOR MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: REXAHN PHARMACEUTICALS, INC., a Delaware corporation; RAZOR MERGER SUB, INC., a Delaware corporation; and OCUPHIRE PHARMA, INC. a Delaware corporation Dated as of June 17, 2020Agreement and Plan of Merger and Reorganization • June 19th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 19th, 2020 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 17, 2020, by and among REXAHN PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), RAZOR MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: DELMAR PHARMACEUTICALS, INC., a Nevada corporation; ADGERO ACQUISITION CORP., a Delaware corporation; and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC. a Delaware corporation Dated as of June 9, 2020Agreement and Plan of Merger and Reorganization • June 10th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 10th, 2020 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 9, 2020, by and among DELMAR PHARMACEUTICALS, INC., a Nevada corporation (“Parent”), ADGERO ACQUISITION CORP., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”). Parent, Merger Sub and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Exhibit A.
Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: Aviragen Therapeutics, Inc., a Delaware corporation; AGORA MERGER SUB, INC., a Delaware corporation; and Vaxart, Inc., a Delaware corporation Dated as of October 27, 2017 PageAgreement and Plan of Merger and Reorganization • May 5th, 2020 • Delaware
Contract Type FiledMay 5th, 2020 Jurisdiction
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: BIOPHARMX CORPORATION, a Delaware corporation; BITI MERGER SUB, INC. a Delaware corporation; and TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company Dated as of January 28, 2020Agreement and Plan of Merger and Reorganization • January 29th, 2020 • BioPharmX Corp • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 29th, 2020 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of January 28, 2020, by and among BIOPHARMX CORPORATION, a Delaware corporation (“Parent”), BITI MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: NEWLINK GENETICS CORPORATION, a Delaware corporation; CYCLONE MERGER SUB, INC., a Delaware corporation; and LUMOS PHARMA, INC., a Delaware corporationAgreement and Plan of Merger and Reorganization • September 30th, 2019 • Newlink Genetics Corp • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 30th, 2019 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of September 30, 2019, by and among NewLink Genetics Corporation, a Delaware corporation (“Parent”), Cyclone Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Lumos Pharma, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GEMPHIRE THERAPEUTICS INC., a Delaware corporation; GR MERGER SUB INC., a Delaware corporation; and NEUROBO PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 24, 2019Agreement and Plan of Merger and Reorganization • July 25th, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 25th, 2019 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 24, 2019, by and among GEMPHIRE THERAPEUTICS INC., a Delaware corporation (“Parent”), GR MERGER SUB INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and NEUROBO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: HISTOGENICS CORPORATION, a Delaware corporation; RESTORE MERGER SUB, INC., a Delaware corporation; and OCUGEN, INC., a Delaware corporation Dated as of April 5, 2019Agreement and Plan of Merger and Reorganization • April 8th, 2019 • Histogenics Corp • Orthopedic, prosthetic & surgical appliances & supplies • Delaware
Contract Type FiledApril 8th, 2019 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of April 5, 2019, by and among Histogenics Corporation, a Delaware corporation (“Parent”), Restore Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Ocugen, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among:Agreement and Plan of Merger and Reorganization • March 7th, 2019 • GTX Inc /De/ • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 7th, 2019 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of March 6, 2019, by and among GTx, Inc., a Delaware corporation (“Parent”) Grizzly Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONAgreement and Plan of Merger and Reorganization • November 26th, 2018 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 26th, 2018 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of November 23, 2018, by and among Edge Therapeutics, Inc., a Delaware corporation (“Parent”), ECHOS MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among:Agreement and Plan of Merger and Reorganization • October 30th, 2017 • Aviragen Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 30th, 2017 Company Industry Jurisdiction